Randomized, double-blind, placebo-controlled study to assess the safety and tolerability of a cell-derived influenza vaccine in healthy adults aged greater than or equal to 18 years and less than or equal to 49 years.

Trial Profile

Randomized, double-blind, placebo-controlled study to assess the safety and tolerability of a cell-derived influenza vaccine in healthy adults aged greater than or equal to 18 years and less than or equal to 49 years.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2010

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 23 Apr 2010 Trial sponsor and affiliate changed from Solvay Pharmaceuticals to Abbott Laboratories as Solvay Pharmaceuticals is acquired by Abbott Laboratories.
    • 29 Jun 2008 Actual study completion date is now 1 May 2008 as reported by ClinicalTrials.gov.
    • 19 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top